Vivos Therapeutics, Inc. Selling and Marketing Expense
Vivos Therapeutics, Inc. (VVOS) reported Selling and Marketing Expense of $155.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-14
- Vivos Therapeutics, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $155.00K, a 40.38% decline year-over-year.
- Vivos Therapeutics, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $249.00K, a 30.45% decline year-over-year.
- Vivos Therapeutics, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $382.00K, a 7.28% decline year-over-year.
- Vivos Therapeutics, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $403.00K, a 16.47% increase year-over-year.
- Vivos Therapeutics, Inc. selling and marketing expense for fiscal 2025 was $1.40M, a 19.12% decline from fiscal 2024.
- Vivos Therapeutics, Inc. selling and marketing expense for fiscal 2024 was $1.73M, a 29.83% decline from fiscal 2023.
- Vivos Therapeutics, Inc. selling and marketing expense for fiscal 2023 was $2.47M, a 53.80% decline from fiscal 2022.
- Vivos Therapeutics, Inc. selling and marketing expense for fiscal 2022 was $5.34M, a 3.80% decline from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 6 month as first filed | Selling and Marketing Expense 9 month | Selling and Marketing Expense 9 month as first filed | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $155.00K 10-Q · filed 2026-08-14 | $404.00K 10-Q · filed 2026-08-14 | $786.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.19M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $249.00K 10-Q · filed 2026-05-20 | $631.00K derived: sum of 2 quarters · filed 2026-05-20 | $1.03M derived: sum of 3 quarters · filed 2026-05-20 | $1.29M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $785.00K derived: sum of 2 quarters · filed 2026-04-15 | $1.04M derived: sum of 3 quarters · filed 2026-08-14 | $1.40M 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | $403.00K 10-Q · filed 2025-11-19 | $663.00K derived: sum of 2 quarters · filed 2026-08-14 | $1.02M 10-Q · filed 2025-11-19 | $1.43M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $260.00K 10-Q · filed 2026-08-14 | $615.00K 10-Q · filed 2026-08-14 | $1.03M derived: sum of 3 quarters · filed 2026-08-14 | $1.38M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $358.00K 10-Q · filed 2026-05-20 | $770.00K derived: sum of 2 quarters · filed 2026-05-20 | $1.12M derived: sum of 3 quarters · filed 2026-05-20 | $1.44M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $758.00K derived: sum of 2 quarters · filed 2026-04-15 | $1.08M derived: sum of 3 quarters · filed 2026-04-15 | $1.73M 10-K · filed 2026-04-15 | ||||
| 2024-09-30 | $346.00K 10-Q · filed 2025-11-19 | $666.00K derived: sum of 2 quarters · filed 2025-11-19 | $1.32M 10-Q · filed 2025-11-19 | $1.93M derived: sum of 4 quarters · filed 2025-11-19 | ||||
| 2024-06-30 | $320.00K 10-Q · filed 2025-08-19 | $973.00K 10-Q · filed 2025-08-19 | $1.58M derived: sum of 3 quarters · filed 2025-08-19 | $2.22M derived: sum of 4 quarters · filed 2025-08-19 | ||||
| 2024-03-31 | $655.00K 10-Q · filed 2025-05-15 | $1.26M derived: sum of 2 quarters · filed 2025-05-15 | $1.90M derived: sum of 3 quarters · filed 2025-05-15 | $2.49M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.25M derived: sum of 2 quarters · filed 2025-03-31 | $1.84M derived: sum of 3 quarters · filed 2025-03-31 | $2.47M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $641.00K 10-Q · filed 2024-11-14 | $1.23M derived: sum of 2 quarters · filed 2024-11-14 | $1.86M 10-Q · filed 2024-11-14 | $3.22M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $590.00K 10-Q · filed 2024-08-14 | $1.22M 10-Q · filed 2024-08-14 | $2.58M derived: sum of 3 quarters · filed 2024-08-14 | $3.68M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $630.00K 10-Q · filed 2024-05-14 | $1.99M derived: sum of 2 quarters · filed 2024-07-30 | $3.09M derived: sum of 3 quarters · filed 2024-07-30 | $4.79M derived: sum of 4 quarters · filed 2024-07-30 | ||||
| 2022-12-31 | $1.35M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-07-30 | $2.46M derived: sum of 2 quarters · filed 2024-07-30 | $4.16M derived: sum of 3 quarters · filed 2024-07-30 | $5.34M 10-K/A · filed 2024-07-30 | ||||
| 2022-09-30 | $1.11M 10-Q · filed 2023-11-14 | $2.81M derived: sum of 2 quarters · filed 2023-11-14 | $3.98M 10-Q · filed 2023-11-14 | $4.88M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.70M 10-Q · filed 2023-08-16 | $2.88M 10-Q · filed 2023-08-16 | $3.77M derived: sum of 3 quarters · filed 2023-08-16 | $5.75M derived: sum of 4 quarters · filed 2023-08-16 | ||||
| 2022-03-31 | $753.00K 10-Q · filed 2023-06-08 | $2.07M derived: sum of 2 quarters · filed 2023-06-08 | $4.05M derived: sum of 3 quarters · filed 2023-06-08 | $5.44M derived: sum of 4 quarters · filed 2023-06-08 | ||||
| 2021-12-31 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $3.29M derived: sum of 2 quarters · filed 2023-03-30 | $4.69M derived: sum of 3 quarters · filed 2023-03-30 | $5.55M 10-K · filed 2023-03-30 | ||||
| 2021-09-30 | $1.98M 10-Q · filed 2022-12-20 | $1.98M 10-Q · filed 2021-11-15 | $3.37M derived: sum of 2 quarters · filed 2022-12-20 | $4.23M 10-Q · filed 2022-12-20 | $4.23M 10-Q · filed 2021-11-15 | $5.05M derived: sum of 4 quarters · filed 2022-12-20 | ||
| 2021-06-30 | $1.40M 10-Q · filed 2022-12-20 | $1.40M 10-Q · filed 2021-08-12 | $2.26M 10-Q · filed 2022-12-20 | $2.26M 10-Q · filed 2021-08-12 | $3.08M derived: sum of 3 quarters · filed 2022-12-20 | $3.51M derived: sum of 4 quarters · filed 2022-12-20 | ||
| 2021-03-31 | $860.00K 10-Q/A · filed 2022-11-25 | $860.16K 10-Q · filed 2021-05-17 | $1.68M derived: sum of 2 quarters · filed 2022-11-25 | $2.11M derived: sum of 3 quarters · filed 2022-11-25 | $2.61M derived: sum of 4 quarters · filed 2022-11-25 | |||
| 2020-12-31 | $820.27K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.25M derived: sum of 2 quarters · filed 2022-03-31 | $1.75M derived: sum of 3 quarters · filed 2022-03-31 | $2.31M 10-K · filed 2022-03-31 | $2.31M 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $431.70K 10-Q · filed 2021-11-15 | $933.89K derived: sum of 2 quarters · filed 2021-11-15 | $1.49M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $502.19K 10-Q · filed 2021-08-12 | $1.06M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $559.84K 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | $2.31M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |